Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rethinking antipsychotic formulary policy.

R A Rosenheck1, D L Leslie, Susan Busch

  • 1Yale Medical School, New Haven, CT, USA. Robert.Rosenheck@Yale.Edu

Schizophrenia Bulletin
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Private Equity-Acquired Residential Treatment Facilities vs Other For-Profit Facilities.

JAMA health forum·2026
Same author

Lifetime Real-World Evidence on Safety and Performance of the First Active Transcutaneous Bone Conduction Implant (BCI), the Bonebridge Covering Conductive to Mixed Hearing Loss (CMHL), and Single-Sided Deafness (SSD): Results From a Long-Term Retrospective Analysis.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026
Same author

Lifetime Real-World Evidence on Safety and Performance of the Only Active Middle Ear Implant (AMEI) Covering Conductive to Sensorineural Hearing Loss: Results From a Long-Term Retrospective Analysis.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

The Bonebridge BCI 602 Safety and Performance 1 Year Post-Implantation in Adults and Children: A Multicentric Post-Market Study.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

A Prospective, Multicenter Clinical Investigation on the Safety and Performance of a New Active Transcutaneous Bone-Anchored Implant System.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

Multicenter study results of the med-el partial ossicular replacement prostheses.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2025
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

The Key to Clozapine Mystery May Lie in its Shape.

Schizophrenia bulletin·2026
See all related articles

Second-generation antipsychotics (SGAs) may not be more effective than first-generation antipsychotics (FGAs) and carry higher risks and costs. A new algorithm for antipsychotic therapy is proposed to address these findings.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Recent research questions the superior efficacy of second-generation antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs).
  • The perceived lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia with SGAs is less supported by evidence than previously assumed.
  • SGAs may present greater metabolic risks and significantly higher costs, potentially outweighing their benefits.

Purpose of the Study:

  • To critically review current research on the comparative effectiveness and safety of SGAs versus FGAs.
  • To propose a revised algorithm for antipsychotic maintenance therapy based on updated evidence.
  • To suggest a framework for implementing treatment changes with standardized documentation and feedback.

Main Methods:

  • Literature review of recent research on antipsychotic efficacy and adverse effects.

Related Experiment Videos

  • Development of a novel algorithm for antipsychotic maintenance therapy.
  • Outline of a cautious implementation strategy for clinical practice.

    • Main Results:

    • Evidence suggests SGAs may not offer superior efficacy over FGAs.
    • The reduced risk profile for EPS and tardive dyskinesia with SGAs is weakly supported.
    • Metabolic side effects and higher costs associated with SGAs are significant concerns.

    Conclusions:

    • A reassessment of antipsychotic treatment guidelines is warranted.
    • A new algorithm prioritizing cost-effectiveness and risk-benefit profiles is proposed.
    • Implementation should involve careful monitoring and physician autonomy, avoiding restrictive formularies.